Clinical trials: Mesothelioma
Malignant Pleural Mesothelioma
A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma
To examine whether the arginine depleting drug, ADI-PEG 20, might be effective as a targeted therapy in patients with ASS-negative malignant pleural mesothelioma.
- Trial name
- ADAM (NCT01279967)
- Testing
- ADI-PEG 20
- Where
- 7 sites in United Kingdom
- Volunteers
- 70 people
- Sponsor
- Barts & The London NHS Trust
Mesothelioma
Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma
This is a randomised Phase II clinical trial to assess and compare efficacy and safety profile of cisplatin and pemetrexed against cisplatin and low-dose gemcitabine in long infusion.
- Trial name
- AGILI (NCT01281800)
- Testing
- Gemcitabine in long infusion
- Where
- Slovenia
- Volunteers
- 72 people
- Sponsor
- Institute of Oncology Ljubljana
Malignant Mesothelioma
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase II trial is studying how well pemetrexed disodium or observation works in…
- Trial name
- NCT01085630
- Testing
- pemetrexed disodium, clinical observation
- Where
- 145 sites in United States
- Volunteers
- 72 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Tumors, Neoplasm Metastasis
Rapamycin With Grapefruit Juice for Advanced Malignancies
The purpose of this study is to determine the highest safe dose of rapamycin when given with a fixed amount of grapefruit juice.
- Trial name
- NCT00375245
- Testing
- Rapamycin (sirolimus), Grapefruit Juice
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Chicago
Malignant Pleural Mesothelioma
Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)
The study is a prospective, single arm, non-randomized, open label phase II trial, designed to study the safety and efficacy of a medical device, the NovoTTF-100L concomitant with Pemetrexed and cisplatin or carboplatin in…
- Trial name
- NCT02397928
- Testing
- NovoTTF-100L device, Pemetrexed, Cisplatin or Carboplatin
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 82 people
- Sponsor
- NovoCure Ltd.
Mesothelioma, Malignant
A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
The purpose of this study is to observe the safety of the combination therapy with Yervoy and Opdivo in Japanese participants for the treatment of unresectable advanced/recurrent malignant pleural mesothelioma (MPM).
- Trial name
- NCT05324436
- Where
- Japan
- Volunteers
- 75 people
- Sponsor
- Bristol-Myers Squibb
Mesothelioma
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
The proposed study will evaluate the safety and feasibility of neoadjuvant nivolumab +/- ipilimumab in resectable MPM. In addition, maintenance nivolumab will be administered for 1 year following completion of standard…
- Trial name
- NCT03918252
- Testing
- Nivolumab Injection, Ipilimumab Injection
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Solid Tumor, Adult, Mesothelioma
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or…
- Conditions
- Solid Tumor, Adult, Mesothelioma, NSCLC
- Trial name
- NCT04665206
- Testing
- VT3989, Nivolumab & Ipilimumab, Osimertinib
- Where
- 12 sites in United States, Australia
- Volunteers
- 434 people
- Sponsor
- Vivace Therapeutics, Inc
Malignant Pleural Mesothelioma
Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma
This is a prospective study evaluating the effect of expression of CD74 and VEGF on outcome of treatment in patients with malignant pleural mesothelioma receiving Pemetrexed/Platinum protocol.
- Trial name
- NCT02761863
- Testing
- CD 74, VEGF detection
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Cutaneous Melanoma, Non-small Cell Lung Cancer
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug.
- Conditions
- Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms
- Trial name
- NCT05571839
- Testing
- PF-08046049
- Where
- 37 sites in United States, Canada and 4 more
- Volunteers
- 41 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy…
- Conditions
- Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
- Trial name
- NCT04104776
- Testing
- Tulmimetostat, Enzalutamide
- Where
- 80 sites in United States, France and 5 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Malignant Pleural Mesothelioma
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
This research is being done to find out if pemetrexed and cisplatin work better when given together with an experimental drug called MORAb-009 in patients with malignant pleural mesothelioma.
- Trial name
- Amatuximab (NCT00738582)
- Testing
- MORAb-009 (Amatuximab), Pemetrexed, Cisplatin
- Where
- 28 sites in United States, Canada and 3 more
- Volunteers
- 89 people
- Sponsor
- Morphotek
Malignant Pleural Effusion, Malignant Mesothelioma
Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors
This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer that has spread to the pleura or pleural mesothelioma.
- Conditions
- Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
- Trial name
- RIOT 4B (NCT07443020)
- Testing
- locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 (IL-2)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Melanoma, Breast Carcinoma
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma
- Trial name
- DUET-2 (NCT03517488)
- Testing
- XmAb20717
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Xencor, Inc.
Solid Organ Tumors
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
The purpose of this research study is to collect information from patient's medical records that had a test called ChemoFx® ordered and to understand how doctors may have used the results of the ChemoFx® to treat patients with…
- Trial name
- NCT01271959
- Where
- 25 sites in United States
- Volunteers
- 167 people
- Sponsor
- Precision Therapeutics
Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung
N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy
In this study we want to investigate the efficacy of N-acetylcysteine (NAC), which is an anti-oxidant, in the prevention of cisplatin-induced neural toxicity, in patients treated for lung cancer with chemotherapy containing…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Mesothelioma
- Trial name
- NAC-PNP (NCT00637624)
- Testing
- N-Acetylcysteine
- Where
- Netherlands
- Volunteers
- 69 people
- Sponsor
- Rijnstate Hospital
Locally Advanced or Metastatic Solid Tumor
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in participants with advanced or metastatic…
- Trial name
- NCT03717415
- Testing
- Rebastinib, Carboplatin
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Non-Small Cell Lung Cancer and Pleural Mesothelioma
Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer
This is an open-label, two-arm, multicenter Phase IA/II dose-escalation study of PTK787 in combination with Pemetrexed alone (Cohort 1) or Pemetrexed and Cisplatin (Cohort 2).
- Trial name
- NCT00281125
- Testing
- PTK787 and Pemetrexed with or without Cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nevada Cancer Institute
Cancer
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
RATIONALE: Using BG00001 to insert the gene for interferon-beta into a person's pleural cavity may improve the body's ability to fight cancer.
- Trial name
- NCT00066404
- Testing
- recombinant adenovirus-hIFN-beta
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine